D.E. Shaw & Co’s Takeda Pharmaceutical TAK Stock Holding History

D.E. Shaw & Co’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,000	Closed	-$273K	–	4476
2020 Q4	$273K	Hold	15,000	–	–	﹤0.01%	3634
2020 Q3	$268K	Hold	15,000	–	–	﹤0.01%	3496
2020 Q2	$269K	Buy	+15,000	New	+$269K	﹤0.01%	3667
2020 Q1	–	Sell	-136,816	Closed	-$2.7M	–	4245
2019 Q4	$2.7M	Hold	136,816	–	–	﹤0.01%	2229
2019 Q3	$2.35M	Hold	136,816	–	–	﹤0.01%	2234
2019 Q2	$2.42M	Hold	136,816	–	–	﹤0.01%	2111
2019 Q1	$2.79M	Buy	+136,816	New	+$2.75M	﹤0.01%	1936

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

D.E. Shaw & Co's TAK Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Takeda Pharmaceutical (TAK) stake by 39% in Q1 2026, selling an estimated $29.7M and leaving 2,602,543 shares worth $48.2M. The position accounts for 0.03% of the portfolio, ranked #677.

D.E. Shaw & Co first reported a position in TAK in Q1 2019 and has held it in 17 quarters since. The position peaked at $66.9M in Q4 2025. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

D.E. Shaw & Co held 2,602,543 shares of Takeda Pharmaceutical worth $48.2M as of Q1 2026.
D.E. Shaw & Co sold 1,691,207 Takeda Pharmaceutical shares in Q1 2026, an estimated $29.7M.
Takeda Pharmaceutical made up 0.03% of D.E. Shaw & Co's portfolio in Q1 2026, its #677 holding.
D.E. Shaw & Co first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 17 quarters since.
D.E. Shaw & Co's Takeda Pharmaceutical position peaked at $66.9M in Q4 2025.
358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.